Capricor Therapeutics Inc.
Organization details
- Legal name
- Capricor Therapeutics Inc.
- Former names
- Nile Therapeutics, Inc. SMI Products Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CAPR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001133869
Board of directors
-
David B. Musket · DirectorSince 2023
-
Earl M. Collier Jr. · DirectorSince 2023
-
Frank Litvack · DirectorSince 2023
-
George W. Dunbar Jr. · DirectorSince 2023
-
Karimah Es Sabar · DirectorSince 2023
-
Linda Marban · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Louis Manzo · DirectorSince 2023
-
Mike Kelliher · DirectorSince 2023
-
Paul Gisbert Auwaerter · DirectorSince 2023
-
Philip J. Gotwals · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
68.6%
-
79.3%
-
81.0%
-
81.2%
-
81.5%
-
82.4%
-
82.8%
-
82.8%
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
OmniAb Inc. Same sectorvia Philip J. Gotwals
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $8,366,256
- 13 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +24,100 | $3.18 | $76,638 |
| Jun 25, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +24,100 | $3.18 | $76,638 |
| Jun 25, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Open-market sale | −24,100 | $30.38 | $732,158 |
| Jun 25, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −24,100 | $30.38 | $732,158 |
| Jun 24, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +400 | $3.18 | $1,272 |
| Jun 24, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +400 | $3.18 | $1,272 |
| Jun 24, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Open-market sale | −400 | $30.00 | $12,000 |
| Jun 24, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −400 | $30.00 | $12,000 |
| Jun 22, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +500 | $3.18 | $1,590 |
| Jun 22, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +500 | $3.18 | $1,590 |
| Jun 22, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Open-market sale | −500 | $30.00 | $15,000 |
| Jun 22, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −500 | $30.00 | $15,000 |
| May 18, 2026 | Bergmann Anthony Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +3,000 | $1.39 | $4,170 |
| May 13, 2026 | Frank Litvack Director | Option exercise | +3,937 | $1.39 | $5,472 |
| May 1, 2026 | Krasney Karen Officer (EVP, GENERAL COUNSEL) | Option exercise | +25,000 | $3.18 | $79,500 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Capricor Therapeutics Inc.
Who is the CEO of Capricor Therapeutics Inc.?
Linda Marban is Capricor Therapeutics Inc.'s CHIEF EXECUTIVE OFFICER.
How many directors are on Capricor Therapeutics Inc.'s board?
Capricor Therapeutics Inc.'s board has 10 directors: David B. Musket, Earl M. Collier Jr., Frank Litvack, George W. Dunbar Jr., Karimah Es Sabar, Linda Marban, Louis Manzo, Mike Kelliher, Paul Gisbert Auwaerter and Philip J. Gotwals.
Are Capricor Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Capricor Therapeutics Inc. insiders made no open-market purchases and sold $8.4 million of shares in 13 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="capricor-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.